EGFR and non-small cell lung carcinoma: The phase III randomized trials OPTIMAL [16] and EURTAC [17] reported that PFS (13.1 months and 9.7 months, respectively) was significantly better than chemotherapy (4.6 months and 5.2 months, respectively) in patients with EGFR-mutated NSCLC receiving first-line erlotinib alone.